



P.17019/01/2022-PvPI
Indian Pharmacopoeia Commission
National Coordination Centre-Pharmacovigilance Programme of India
(Ministry of Health & Family Welfare, Govt. of India)

Email: signal.pvpi-ipc@gov.in, lab.ipc@gov.in, Website: www.ipc@gov.in, Tel. No. 0120-2783400

Sector - 23, Raj Nagar,
Ghaziabad - 201002, U.P.
Dated: 17th June, 2022

Monthly Drug Safety Alert

The preliminary analysis of Adverse Drug Reaction (ADR) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

Table

Sl. No.	Suspected Drug	Indication	Adverse Drug Reaction
1.	Trimetazidine	<ul style="list-style-type: none">Ischaemic heart disease, angina pectoris, sequelae of infarction.Cardiac drug indicated in the treatment of angina pectoris and intermittent claudication.	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “ADR PvPI” and PvPI Helpline No. **1800-180-3024**.